Oculyra - Florrax Pharmaceutical

Manufacturer
Florrax Pharmaceutical
Effective date
2026-09-11
Label type
DIETARY SUPPLEMENT
Version
1
Source
daily-update
Hydrated at
2026-09-16 01:01:07

Label at a glance#

ProductOculyra
Active ingredientASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL ACETATE, D-, FOLIC ACID, METHYLCOBALAMIN, ZINC, COPPER, MAGNESIUM GLYCINATE, LUTEIN, ZEAXANTHIN, ZEAXANTHIN, MESO-, ASTAXANTHIN, SCHIZOCHYTRIUM DHA OIL, BILBERRY, SAFFRON, ACETYLCYSTEINE, ALPHA LIPOIC ACID
Label structure7 sections

Label contents#

Full prescribing information#

Supplement Facts

HEALTH CLAIM SECTION

Oculyra Tablets

Dispensed by Prescription

pdp
pdp

Description:

STATEMENT OF IDENTITY SECTION

Oculyra Eye-Health Nutritional Supplement Tablets are orally administered tablets dispensed in plastic bottles of 30 count.

84460-0951-30

Reserved for Professional Recommendation

Oculyra Eye-Health Nutritional Supplement Tablets should be administered under the supervision of a licensed medical practitioner.

Oculyra is an orally administered eye-health nutritional supplement formulation containing vitamins, minerals, carotenoids, antioxidants, botanical extracts, and algal DHA. The formulation is intended to provide nutritional support for eye health and to supplement dietary intake where advanced nutritional supplementation is recommended.

This listed product is not a National Drug Code, but instead has merely been formatted to comply with standard industry practice for pharmacy and insurance computer systems.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

All recommendations or prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under the supervision of a licensed healthcare practitioner. There are no implied or explicit claims of therapeutic equivalence.

Manufactured for: Florrax Pharmaceutical, Dallas, TX.

Warnings:

WARNINGS SECTION

This product is contraindicated in individuals with a known hypersensitivity to any of the ingredients contained in Oculyra.

Oculyra should be used under the direction and supervision of a licensed healthcare practitioner. Consult a licensed healthcare practitioner before use if you have a medical condition, are pregnant or lactating, are trying to conceive, are under 18 years of age, or are taking prescription or over-the-counter medications or other dietary supplements.

Do not exceed the recommended dosage unless directed by a licensed healthcare practitioner.

Keep out of reach of children. Do not use if the safety seal is broken or missing.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Dosage:

DOSAGE & ADMINISTRATION SECTION

Take two (2) tablets daily, or as directed by a licensed healthcare practitioner.

Oculyra is intended for oral administration. Do not exceed the recommended dosage unless otherwise directed by a licensed healthcare practitioner.

Packaging:

PRECAUTIONS SECTION

CONTRAINDICATIONS

Oculyra is contraindicated in individuals with a known hypersensitivity to any of the ingredients contained in the formulation.

PRECAUTIONS

Oculyra should be used under the direction and supervision of a licensed healthcare practitioner. Consult a licensed healthcare practitioner before use if you have a medical condition, are pregnant or lactating, are trying to conceive, are under 18 years of age, or are taking medications or other dietary supplements.

Do not exceed the recommended dosage unless otherwise directed by a licensed healthcare practitioner.

ADVERSE REACTIONS

Individuals sensitive to any ingredient in Oculyra may experience an allergic or hypersensitivity reaction. Discontinue use and consult a licensed healthcare practitioner if an adverse reaction occurs.

KEEP OUT OF THE REACH OF CHILDREN.

Storage:

SAFE HANDLING WARNING SECTION

Store at 20° - 25° C (68° - 77° F); excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature]

Packaging:

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

pdp
pdp

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeEAN-130385477000228GTIN-13: 0385477000228
EAN-13: 0385477000228
GTIN-12: 385477000228
UPC-A: 385477000228
GTIN storage (14 digits): 00385477000228
oculyra-2.jpg

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 26 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
84460-95184460-951-30

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 23 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 4 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Ascorbic AcidASCORBIC ACIDRenova Pharmaceuticals LLCa6481bae-2397-44c7-a51d-4f47ad91bd2c2026-08-19Warnings, Adverse reactionsName fallback
generic name: ASCORBIC ACID
AscorASCORBIC ACIDMcGuff Pharmaceuticals, Inc.388aad52-fc01-4784-9791-1dbc80c693062026-05-29Warnings, Adverse reactionsName fallback
generic name: ASCORBIC ACID
Ascorbic AcidASCORBIC ACIDFresenius Kabi USA, LLC1606e29f-0e80-4069-b688-daab9cbff20a2025-12-17Warnings, Adverse reactionsName fallback
generic name: ASCORBIC ACID
Skin Renewing SerumASCORBIC ACIDGuangzhou Danting Bath&Body Care Industry Co. Ltd396c2a8d-ac95-cbef-e063-6294a90aff392025-08-23WarningsName fallback
generic name: ASCORBIC ACID

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.